65,437 trials
Healthy
Primary: Total Dabigatran: Area Under the Concentration-time Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss) — 551; 817; 689; 660 ng*h/mL — p=0.9456
Exudative Age-Related Macular Degeneration · Focal Vitreomacular Adhesion
Primary: Proportion of Subjects With Focal Vitreomacular Adhesion (VMA) Release by Day 28 — 24.3; 12.0 percentage of subjects — p=0.262
Rabies
Primary: Geometric Mean Rabies Virus Neutralizing Antibody (RVNA) Concentration in Each of the Zagreb and Essen Groups on Study Day 14 — 0.09; 0.099; 12; 12 IU/mL
Acellular Pertussis · Haemophilus Influenzae Type b · Tetanus
Primary: Number of Subjects Reporting Solicited Local Symptoms — 95; 82; 52 Participants
Diabetic Foot Ulcers · Diabetic Foot Wounds
Primary: Mean Percent Change in Wound Area — -68; -36; -61; -46 percentage of change in wound area
Multiple Sclerosis · Cognitive Ability, General
Primary: Primary Outcome is Performance on the Interference Condition of the Stroop, the Long Delay Free Recall Portion of the California Verbal Learning Test II, the 2 Second…
Major Depressive Disorder (MDD)
Primary: Percent Change in Hamilton Depression Rating Scale (HAMD-17) at Baseline and the End of Week 4 of Treatment. — -53.8; -53.1; -24.2 % change in HAM-D score
Acute Graft Versus Host Disease
Primary: Percentage of Participants With Evidence of Acute Graft Versus Host Disease (aGVHD), Post Transplant — 43; 89 percentage of participants
Alzheimer's Disease
Primary: Change in the Area Under the Curve of Plasma Aβ1-40 in the 2 or 4 Weeks After the Last Treatment Infusion From the Trough Level Prior to the Last Treatment Infusion…
Metastatic Pancreatic Cancer
Primary: Toxicity (Number of Patients Who Experiened DLTs) — 0; 1; 1; 2 participants
Pneumococcal Infections
Primary: Carriage Due to Any Pneumococcal Serotype Included in the Ten-valent Pneumococcal Conjugate Vaccine (PCV10) Vaccine in Older Siblings of Children Vaccinated With Infant…
Pulmonary Arterial Hypertension
Primary: Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) — 80.1; 89.3…
Metastatic Breast Cancer · Recurrent Breast Cancer · Stage IV Breast Cancer
Primary: Proportion of Patients With Confirmed Tumor Response — 1; 20 Participants
Moderate to Severe Chronic Plaque Psoriasis
Primary: Percentage of Participants With at Least 50 Percent (%) Reduction in Psoriasis Area Severity Index (PASI) Score at Week 12 or Early Termination — 20.0; 20.0; 17.9; 20.0…
Breast Cancer
Primary: Progression-free Survival — 6.2; 3.3 Months — p=<0.0001